BioSpecifics Technologies Corp Company Profile (NASDAQ:BSTC)

About BioSpecifics Technologies Corp (NASDAQ:BSTC)

BioSpecifics Technologies Corp logoBioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren's contracture and Peyronie's disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:BSTC
  • CUSIP: 09093110
  • Web:
  • Market Cap: $347.24 million
  • Outstanding Shares: 7,164,000
Average Prices:
  • 50 Day Moving Avg: $47.23
  • 200 Day Moving Avg: $49.90
  • 52 Week Range: $41.00 - $58.79
  • Trailing P/E Ratio: 29.74
  • Foreward P/E Ratio: 28.68
  • P/E Growth: 1.36
Sales & Book Value:
  • Annual Revenue: $27.73 million
  • Price / Sales: 12.52
  • Book Value: $8.66 per share
  • Price / Book: 5.60
  • EBITDA: $18.65 million
  • Net Margins: 43.06%
  • Return on Equity: 20.65%
  • Return on Assets: 17.98%
  • Current Ratio: 23.09%
  • Quick Ratio: 23.09%
  • Average Volume: 23,757 shs.
  • Beta: 1.76
  • Short Ratio: 4.98

Frequently Asked Questions for BioSpecifics Technologies Corp (NASDAQ:BSTC)

What is BioSpecifics Technologies Corp's stock symbol?

BioSpecifics Technologies Corp trades on the NASDAQ under the ticker symbol "BSTC."

How were BioSpecifics Technologies Corp's earnings last quarter?

BioSpecifics Technologies Corp (NASDAQ:BSTC) released its quarterly earnings results on Wednesday, March, 15th. The company reported $0.40 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.38 by $0.02. The company earned $6.62 million during the quarter, compared to analysts' expectations of $6.76 million. BioSpecifics Technologies Corp had a net margin of 43.06% and a return on equity of 20.65%. View BioSpecifics Technologies Corp's Earnings History.

When will BioSpecifics Technologies Corp make its next earnings announcement?

BioSpecifics Technologies Corp is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for BioSpecifics Technologies Corp.

Where is BioSpecifics Technologies Corp's stock going? Where will BioSpecifics Technologies Corp's stock price be in 2017?

1 brokerages have issued 12-month price objectives for BioSpecifics Technologies Corp's shares. Their forecasts range from $72.00 to $72.00. On average, they anticipate BioSpecifics Technologies Corp's share price to reach $72.00 in the next twelve months. View Analyst Ratings for BioSpecifics Technologies Corp.

What are analysts saying about BioSpecifics Technologies Corp stock?

Here are some recent quotes from research analysts about BioSpecifics Technologies Corp stock:

  • 1. According to Zacks Investment Research, "BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (FDA) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for potential use as pharmaceuticals. " (10/10/2017)
  • 2. HC Wainwright analysts commented, "We have adjusted our revenue projection for BSTC accordingly, and our current 2017 revenue projection is $28.0M vs. the prior $29.6M, suggesting 7% YoY growth, while our 2018 revenue estimate is now $29.4M vs. the prior $32M." (8/10/2017)

Who are some of BioSpecifics Technologies Corp's key competitors?

Who are BioSpecifics Technologies Corp's key executives?

BioSpecifics Technologies Corp's management team includes the folowing people:

  • Thomas L. Wegman, President, Principal Executive Officer, Principal Financial Officer, Director
  • Mark N. Wegman Ph.D., Director
  • Toby Wegman, Director
  • Jennifer M. Chao, Independent Director
  • Paul A. Gitman M.D., Independent Director
  • George M. Gould J.D., Independent Director

How do I buy BioSpecifics Technologies Corp stock?

Shares of BioSpecifics Technologies Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioSpecifics Technologies Corp's stock price today?

One share of BioSpecifics Technologies Corp stock can currently be purchased for approximately $48.47.

MarketBeat Community Rating for BioSpecifics Technologies Corp (NASDAQ BSTC)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  44 (Vote Underperform)
Total Votes:  146
MarketBeat's community ratings are surveys of what our community members think about BioSpecifics Technologies Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioSpecifics Technologies Corp (NASDAQ:BSTC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $72.00 (48.55% upside)
Consensus Price Target History for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Price Target History for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Analysts' Ratings History for BioSpecifics Technologies Corp (NASDAQ:BSTC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017HC WainwrightSet Price TargetBuy$72.00HighView Rating Details
8/10/2016Rodman & RenshawReiterated RatingBuy$60.00N/AView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Earnings by Quarter for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Earnings History by Quarter for BioSpecifics Technologies Corp (NASDAQ BSTC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2017Q4 2016$0.38$0.40$6.76 million$6.62 millionViewN/AView Earnings Details
11/9/2016Q3 2016$0.41$0.42$6.95 million$6.88 millionViewListenView Earnings Details
8/9/2016Q216$0.35$0.35$6.25 million$6.20 millionViewN/AView Earnings Details
5/10/2016Q116$0.37$0.39$6.25 million$6.60 millionViewListenView Earnings Details
3/14/2016Q416$0.33$0.36$4.60 million$6.10 millionViewListenView Earnings Details
11/9/2015Q315$0.39$7.51 million$6.30 millionViewN/AView Earnings Details
8/10/2015Q215$0.44$0.24$2.60 million$4.70 millionViewListenView Earnings Details
5/11/2015Q414$0.32$2.30 million$5.60 millionViewN/AView Earnings Details
11/10/2014Q314$0.19$0.20$4.00 million$4.00 millionViewN/AView Earnings Details
8/11/2014Q214$0.12$0.08$2.91 million$2.70 millionViewN/AView Earnings Details
5/8/2014Q114$0.07$0.11$2.46 million$2.80 millionViewN/AView Earnings Details
3/6/2014$0.17$0.25ViewN/AView Earnings Details
11/12/2013Q3$0.04$0.17ViewListenView Earnings Details
8/8/2013Q2 2013$0.02$0.15ViewN/AView Earnings Details
5/10/2013Q1 2013$0.18$0.19ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Current Year EPS Consensus Estimate: $1.59 EPS
Next Year EPS Consensus Estimate: $1.69 EPS


Dividend History for BioSpecifics Technologies Corp (NASDAQ:BSTC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Insider Ownership Percentage: 21.54%
Institutional Ownership Percentage: 55.95%
Insider Trades by Quarter for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Institutional Ownership by Quarter for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Insider Trades by Quarter for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/29/2016Thomas WegmanInsiderSell20,000$48.16$963,200.00View SEC Filing  
11/29/2016Toby WegmanDirectorSell10,000$48.08$480,800.00View SEC Filing  
9/15/2016Thomas WegmanInsiderSell3,100$41.21$127,751.00View SEC Filing  
9/13/2016Thomas WegmanInsiderSell3,605$37.55$135,367.75View SEC Filing  
9/2/2016Thomas WegmanInsiderSell9,201$37.53$345,313.53View SEC Filing  
8/30/2016Thomas WegmanInsiderSell4,299$37.54$161,384.46View SEC Filing  
8/24/2016Thomas WegmanPresidentSell4,173$38.08$158,907.84View SEC Filing  
8/23/2016Thomas WegmanPresidentSell4,100$38.60$158,260.00View SEC Filing  
5/18/2016Thomas WegmanMajor ShareholderSell50,000$33.01$1,650,500.00View SEC Filing  
5/18/2016Toby WegmanDirectorSell25,000$33.01$825,250.00View SEC Filing  
11/30/2015Thomas WegmanCEOSell2,000$50.00$100,000.00View SEC Filing  
11/23/2015Thomas WegmanCEOSell14,000$50.09$701,260.00View SEC Filing  
11/18/2015Thomas WegmanCEOSell10,849$50.08$543,317.92View SEC Filing  
11/16/2015Thomas WegmanCEOSell27,151$52.44$1,423,798.44View SEC Filing  
7/20/2015Paul GitmanDirectorSell8,692$53.00$460,676.00View SEC Filing  
6/23/2015Paul GitmanDirectorSell36,308$51.78$1,880,028.24View SEC Filing  
5/29/2015Paul GitmanDirectorSell15,000$46.76$701,400.00View SEC Filing  
5/27/2015Paul GitmanDirectorSell24,000$42.00$1,008,000.00View SEC Filing  
1/23/2015Paul GitmanDirectorSell5,887$41.00$241,367.00View SEC Filing  
1/16/2015Paul GitmanDirectorSell4,113$41.00$168,633.00View SEC Filing  
11/24/2014Toby WegmanDirectorSell12,050$39.07$470,793.50View SEC Filing  
11/14/2014Michael SchamrothDirectorSell5,200$39.20$203,840.00View SEC Filing  
11/14/2014Thomas WegmanMajor ShareholderSell40,000$38.96$1,558,400.00View SEC Filing  
6/20/2014Jeffrey Kenneth VogelInsiderSell88,329$27.43$2,422,864.47View SEC Filing  
6/12/2014Paul GitmanDirectorSell10,000$28.00$280,000.00View SEC Filing  
6/4/2014Henry MorganDirectorSell17,940$27.00$484,380.00View SEC Filing  
6/2/2014Henry MorganDirectorSell2,060$27.01$55,640.60View SEC Filing  
5/29/2014Henry MorganDirectorSell20,000$27.03$540,600.00View SEC Filing  
5/19/2014Henry MorganDirectorSell20,000$25.84$516,800.00View SEC Filing  
1/23/2014Paul GitmanDirectorSell10,000$25.00$250,000.00View SEC Filing  
12/9/2013Paul GitmanDirectorSell15,000$23.00$345,000.00View SEC Filing  
11/11/2013Paul GitmanDirectorSell5,000$20.00$100,000.00View SEC Filing  
9/5/2013Henry MorganDirectorSell17,850$18.48$329,868.00View SEC Filing  
9/3/2013Henry MorganDirectorSell2,150$18.35$39,452.50View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Latest Headlines for BioSpecifics Technologies Corp (NASDAQ:BSTC)
DateHeadline logoBiospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : October 18, 2017 - October 18 at 6:05 PM logoBioSpecifics Technologies Corp (BSTC) Raised to Hold at Zacks Investment Research - October 10 at 8:24 PM logoBiospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : October 3, 2017 - October 3 at 8:35 AM logoOne Thing To Consider Before Buying BioSpecifics Technologies Corp (BSTC) - October 2 at 7:29 PM logoBioSpecifics Technologies Corp. to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference - September 20 at 5:34 PM logoBiospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : September 18, 2017 - September 18 at 5:07 PM logoShould You Buy BioSpecifics Technologies Corp (BSTC) At This PE Ratio? - September 15 at 10:11 PM logoBioSpecifics Tech (BSTC) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow - September 14 at 4:08 AM logoBiospecifics Technologies Corp. :BSTC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 - September 13 at 5:58 PM logoBioSpecifics Technologies Corp. Reports Second Quarter 2017 Financial Results - August 9 at 4:56 PM logoBiospecifics Technologies Corp. – Value Analysis (NASDAQ:BSTC) : August 4, 2017 - August 3 at 11:19 PM logoBiospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : July 21, 2017 - July 21 at 6:21 PM logo BioSpecifics Technologies Corp (NASDAQ:BSTC) Given Average Recommendation of "Strong Buy" by Brokerages - July 21 at 11:18 AM logoETFs with exposure to Biospecifics Technologies Corp. : July 11, 2017 - July 11 at 5:47 PM logoBiospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : July 10, 2017 - July 10 at 3:15 PM logoBioSpecifics Technologies (BSTC) Presents At Jefferies 2017 Global Healthcare Conference - June 10 at 2:39 AM logoBRIEF-Biospecifics Technologies reports Q1 earnings per share $0.46 - May 11 at 4:38 PM logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 10-K, Annual Report - March 16 at 10:44 PM logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement - March 15 at 9:25 PM logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events - February 16 at 8:54 AM logoBiospecifics Technologies (BSTC) Reports Statistically Significant Results from Phase 2b Study of CCH in Patients with Cellulite - November 19 at 12:23 PM logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - November 14 at 7:32 AM logoBioSpecifics Technologies' (BSTC) Management on Q3 2016 Results - Earnings Call Transcript - November 10 at 3:21 PM logoQ3 2016 Biospecifics Technologies Corp Earnings Release - Before Market Open - November 9 at 1:04 PM logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement - November 7 at 3:35 PM logoFoamix Pharmaceuticals (FOMX) Jumps: Stock Rises 15.7% - September 13 at 8:51 AM logoNew Strong Buy Stocks for September 7th - September 7 at 10:32 AM logoDipexium Pharmaceuticals (DPRX) in Focus: Stock Gains 8.5% - September 1 at 12:28 PM logoWeakness Seen in Jazz Pharmaceuticals (JAZZ) Estimates: Should You Stay Away? - August 29 at 3:20 PM logoQ2 2016 Biospecifics Technologies Corp Earnings Release - Before Market Open - August 9 at 12:56 PM logoBioSpecifics Technologies Corp. Has A 6-Year Expiration Date - August 3 at 12:41 PM logoBioSpecifics Technologies Reveals Positive Top-Line Results From Stage 2 Study Of CCH For Treatment of Human Lipoma - June 13 at 10:19 AM logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders - June 3 at 1:09 PM logoBiospecifics Technologies (BSTC) Announces Publication of Data for Uterine Fibroid Treatment with CCH - May 31 at 4:00 PM logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits - May 31 at 3:04 PM



BioSpecifics Technologies Corp (BSTC) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.